Graves Ophthalmopathy Pipeline Insight

DelveInsight’s, “Graves Ophthalmopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Graves Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Graves Ophthalmopathy Understanding

Graves’ Ophthalmopathy: Overview

Graves’ ophthalmopathy, also called Graves’ orbitopathy or Thyroid-associated orbitopathy (TAO), is part of an autoimmune process that can affect the orbital and periorbital tissue, the thyroid gland, and, rarely, the pretibial skin or digits. Generally, occur in patients with hyperthyroidism or a history of hyperthyroidism. Risk factors for thyroid-associated orbitopathy include increased age of onset, duration of Graves’ hyperthyroidism, and smoking. The ocular manifestations of thyroid-associated orbitopathy include eyelid retraction, proptosis, chemosis, periorbital edema, and altered ocular motility with significant functional, social, and cosmetic consequences. The first step in treatment is to reverse the hyperthyroidism with either medication or surgery to remove the thyroid.


"Graves’ ophthalmopathy- Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Graves’ ophthalmopathy pipeline landscape is provided which includes the disease overview and Graves’ ophthalmopathy treatment guidelines. The assessment part of the report embraces, in depth Graves’ ophthalmopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Graves’ ophthalmopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Graves Ophthalmopathy R&D. The therapies under development are focused on novel approaches to treat/improve Graves Ophthalmopathy.

Graves Ophthalmopathy Emerging Drugs Chapters

his segment of the Graves Ophthalmopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Graves Ophthalmopathy Emerging Drugs


Batoclimab (RVT-1401): Immunovant

FcRn is the primary protein responsible for preventing the degradation of IgG antibodies and albumin, the most abundant protein found in the blood. The role of FcRn is to bind to the IgG antibodies in the endosome, and transport them to the cell surface, where they are released back into circulation. RVT-1401 is designed to selectively bind to and inhibit FcRn, thus blocking the recycling of IgG antibodies. Currently, in phase 2 of clinical trials for the treatment of Graves Ophthalmopathy.

Further product details are provided in the report……..

Graves Ophthalmopathy: Therapeutic Assessment

This segment of the report provides insights about the different Graves Ophthalmopathy drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Graves Ophthalmopathy

There are approx. 3+ key companies which are developing the therapies for Graves Ophthalmopathy. The companies which have their Graves Ophthalmopathy drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Immunovant and others.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Graves Ophthalmopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Parenteral
  • Intramuscular
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Small molecules
  • Peptides
  • Polymer
  • Gene Therapy
  • Monoclonal antibodies
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Graves Ophthalmopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Graves Ophthalmopathy therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Graves Ophthalmopathy drugs.

Graves Ophthalmopathy Report Insights

  • Graves Ophthalmopathy Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Graves Ophthalmopathy Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Graves Ophthalmopathy drugs?
  • How many Graves Ophthalmopathy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Graves Ophthalmopathy?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Graves Ophthalmopathy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Graves Ophthalmopathy and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Graves Ophthalmopathy: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Graves Ophthalmopathy – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Graves Ophthalmopathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Graves Ophthalmopathy Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

RVT-1410: Immunovant

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Graves Ophthalmopathy Key Companies

Graves Ophthalmopathy Key Products

Graves Ophthalmopathy- Unmet Needs

Graves Ophthalmopathy- Market Drivers and Barriers

Graves Ophthalmopathy- Future Perspectives and Conclusion

Graves Ophthalmopathy Analyst Views

Graves Ophthalmopathy Key Companies

Appendix

List of Table

Table 1: Total Products for Graves Ophthalmopathy

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Graves Ophthalmopathy

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Immunovant

  • Tags:
  • Graves' Ophthalmopathy Pipeline
  • Graves' Ophthalmopathy clinical tr...
  • Graves' Ophthalmopathy companies
  • Graves' Ophthalmopathy drugs
  • Graves' Ophthalmopathy therapies
  • Graves' Ophthalmopathy treatment a...
  • Graves' Ophthalmopathy pipeline dr...
  • Graves' Ophthalmopathy pipeline co...

Forward to Friend

Need A Quote